• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对2019冠状病毒病疫苗研发的洞察:从实验室到临床的转化

Insights into COVID-19 vaccines development: Translation from benchside to bedside.

作者信息

Houssein Marwa, Al Hossainy Aya El Asir, Al Soussi Jana, El Batch Jana, El-Samadi Lana, El Imam Sherine, Fakih Rawan, Dakdouk Hoda, Khalil Mahmoud

机构信息

Department of Biological Sciences, Faculty of Science, Beirut Arab University, Beirut, Lebanon.

Department of General Sciences and English Language, College of Applied Sciences, Al Maarefa University, Riyadh, Saudi Arabia.

出版信息

Health Sci Rev (Oxf). 2022 Sep;4:100040. doi: 10.1016/j.hsr.2022.100040. Epub 2022 Jul 10.

DOI:10.1016/j.hsr.2022.100040
PMID:35856085
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9271228/
Abstract

Over the past decades, the rapid pace of vaccine development saved 37 million lives, mostly children. The ongoing corona virus disease (COVID-19) pandemic caused the death of more than 4 million worldwide. During 2020, to encounter the pandemic, scientists developed more than 300 vaccines projects against SARS-CoV (severe acute respiratory syndrome coronavirus 2). In 2021, the results emerging from the clinical trials led to the approval and rollout of few vaccines in different countries. To date, at least one dose of a COVID-19 vaccine has been received by more than 3.81 billion people worldwide, equal to about 49.7 percent of the world population. This review was written to the aim of providing a snapshot of COVID-19 disease, highlighting the well-known vaccines, and, finally understanding the effect of mix and match vaccines from different types.

摘要

在过去几十年里,疫苗研发的快速步伐挽救了3700万人的生命,其中大多数是儿童。目前的冠状病毒病(COVID-19)大流行在全球造成了400多万人死亡。2020年期间,为应对这一流行病,科学家们开展了300多个针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的疫苗项目。2021年,临床试验的结果导致少数疫苗在不同国家获得批准并推出。迄今为止,全球超过38.1亿人至少接种了一剂COVID-19疫苗,约占世界人口的49.7%。撰写这篇综述的目的是提供COVID-19疾病的概况,突出知名疫苗,并最终了解不同类型混合搭配疫苗的效果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b59/9271228/08b090c2daed/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b59/9271228/11321e495a6b/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b59/9271228/5ea1f2b39860/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b59/9271228/cf1025ef4e89/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b59/9271228/2b2830269787/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b59/9271228/08b090c2daed/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b59/9271228/11321e495a6b/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b59/9271228/5ea1f2b39860/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b59/9271228/cf1025ef4e89/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b59/9271228/2b2830269787/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9b59/9271228/08b090c2daed/gr5_lrg.jpg

相似文献

1
Insights into COVID-19 vaccines development: Translation from benchside to bedside.对2019冠状病毒病疫苗研发的洞察:从实验室到临床的转化
Health Sci Rev (Oxf). 2022 Sep;4:100040. doi: 10.1016/j.hsr.2022.100040. Epub 2022 Jul 10.
2
Comparison of IgA, IgG, and Neutralizing Antibody Responses Following Immunization With Moderna, BioNTech, AstraZeneca, Sputnik-V, Johnson and Johnson, and Sinopharm's COVID-19 Vaccines.比较接种 Moderna、BioNTech、阿斯利康、卫星-V、强生和中国国药的 COVID-19 疫苗后 IgA、IgG 和中和抗体反应。
Front Immunol. 2022 Jun 21;13:917905. doi: 10.3389/fimmu.2022.917905. eCollection 2022.
3
COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.COVID-19 疫苗:辉瑞/生物科技和 Moderna 疫苗的生物学、药理学特征和不良反应比较。
Eur Rev Med Pharmacol Sci. 2021 Feb;25(3):1663-1669. doi: 10.26355/eurrev_202102_24877.
4
The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.新冠疫苗的快速研发和早期成功为加速癌症治疗机制带来了希望。
Arch Razi Inst. 2021 Mar;76(1):1-6. doi: 10.22092/ari.2021.353761.1612. Epub 2021 Mar 1.
5
Cardiovascular Complications of SARS-CoV-2 Vaccines: An Overview.2019冠状病毒病疫苗的心血管并发症:概述
Cardiol Ther. 2022 Mar;11(1):13-21. doi: 10.1007/s40119-021-00248-0. Epub 2021 Nov 29.
6
A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson.SARS-CoV-2 疫苗全面综述:辉瑞、莫德纳和强生。
Hum Vaccin Immunother. 2022 Dec 31;18(1):2002083. doi: 10.1080/21645515.2021.2002083. Epub 2022 Feb 7.
7
The Safety and Effectiveness of mRNA Vaccines Against SARS-CoV-2.针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的信使核糖核酸(mRNA)疫苗的安全性和有效性
Cureus. 2023 Sep 20;15(9):e45602. doi: 10.7759/cureus.45602. eCollection 2023 Sep.
8
Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary-the HUN-VE study.匈牙利五种 SARS-CoV-2 疫苗的全国有效性- HUN-VE 研究。
Clin Microbiol Infect. 2022 Mar;28(3):398-404. doi: 10.1016/j.cmi.2021.11.011. Epub 2021 Nov 25.
9
Anti-Coronavirus Vaccines: Past Investigations on SARS-CoV-1 and MERS-CoV, the Approved Vaccines from BioNTech/Pfizer, Moderna, Oxford/AstraZeneca and others under Development Against SARSCoV- 2 Infection.抗冠状病毒疫苗:对 SARS-CoV-1 和 MERS-CoV 的既往研究,BioNTech/Pfizer、Moderna、牛津/阿斯利康等公司已批准的针对 SARS-CoV-2 感染的疫苗,以及其他正在研发中的疫苗。
Curr Med Chem. 2022;29(1):4-18. doi: 10.2174/0929867328666210521164809.
10
The Effect of Age, Gender and Comorbidities Upon SARS-CoV-2 Spike Antibody Induction After Two Doses of Sinopharm Vaccine and the Effect of a Pfizer/BioNtech Booster Vaccine.年龄、性别和合并症对两剂国药疫苗接种后 SARS-CoV-2 刺突抗体诱导的影响,以及辉瑞/生物科技加强疫苗的影响。
Front Immunol. 2022 May 30;13:817597. doi: 10.3389/fimmu.2022.817597. eCollection 2022.

本文引用的文献

1
The Emergence of Sars-CoV-2 Variant Lambda (C.37) in South America.南美出现新冠病毒拉姆达变种(C.37)
Microbiol Spectr. 2021 Oct 31;9(2):e0078921. doi: 10.1128/Spectrum.00789-21. Epub 2021 Oct 27.
2
Emerging SARS-CoV-2 Variants: A Review of Its Mutations, Its Implications and Vaccine Efficacy.新型严重急性呼吸综合征冠状病毒2(SARS-CoV-2)变体:其突变、影响及疫苗效力综述
Vaccines (Basel). 2021 Oct 18;9(10):1195. doi: 10.3390/vaccines9101195.
3
Genetic Insights into the Middle East Respiratory Syndrome Coronavirus Infection among Saudi People.
沙特人群中东呼吸综合征冠状病毒感染的遗传学见解
Vaccines (Basel). 2021 Oct 17;9(10):1193. doi: 10.3390/vaccines9101193.
4
Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine.AZD1222(ChAdOx1 nCoV-19)新冠疫苗的 3 期安全性和疗效。
N Engl J Med. 2021 Dec 16;385(25):2348-2360. doi: 10.1056/NEJMoa2105290. Epub 2021 Sep 29.
5
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase.mRNA-1273 新型冠状病毒疫苗在盲法阶段完成时的效力。
N Engl J Med. 2021 Nov 4;385(19):1774-1785. doi: 10.1056/NEJMoa2113017. Epub 2021 Sep 22.
6
Binding and entering: COVID finds a new home.结合与进入:新冠病毒找到了新家。
PLoS Pathog. 2021 Aug 30;17(8):e1009857. doi: 10.1371/journal.ppat.1009857. eCollection 2021 Aug.
7
Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants.mRNA-1273疫苗诱导的针对SARS-CoV-2变体的抗体的持久性。
Science. 2021 Sep 17;373(6561):1372-1377. doi: 10.1126/science.abj4176. Epub 2021 Aug 13.
8
Developmental and reproductive safety of AZD1222 (ChAdOx1 nCoV-19) in mice.AZD1222(ChAdOx1 nCoV-19)在小鼠中的发育和生殖安全性。
Reprod Toxicol. 2021 Sep;104:134-142. doi: 10.1016/j.reprotox.2021.07.010. Epub 2021 Jul 26.
9
Alpha, Beta, Delta, Gamma: What's important to know about SARS-CoV-2 variants of concern?阿尔法、贝塔、德尔塔、伽马:关于新冠病毒变异株,需要了解哪些重要信息?
CMAJ. 2021 Jul 12;193(27):E1059-E1060. doi: 10.1503/cmaj.1095949.
10
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar.mRNA-1273 新冠病毒疫苗对卡塔尔 B.1.1.7 和 B.1.351 变异株及重症新冠疾病的有效性
Nat Med. 2021 Sep;27(9):1614-1621. doi: 10.1038/s41591-021-01446-y. Epub 2021 Jul 9.